Results 1 to 10 of about 17,740 (123)
Actinium-225-PSMA versus lutetium-177-PSMA radioligand therapy for metastatic castration-resistant prostate cancer: results of an observational study [PDF]
Frontiers in OncologyBackgroundProstate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with Lutetium-177 (177Lu) and Actinium-225 (225Ac) is increasingly used in metastatic castration-resistant prostate cancer (mCRPC), but head-to-head prospective data ...
Tatiana Yu Kochetova +7 more
doaj +2 more sources
Radiolabeled PSMA Inhibitors [PDF]
Cancers, 2021 PSMA has shown to be a promising target for diagnosis and therapy (theranostics) of prostate cancer. We have reviewed developments in the field of radio- and fluorescence-guided surgery and targeted photodynamic therapy as well as multitargeting PSMA inhibitors also addressing albumin, GRPr and integrin αvβ3.
Oliver C. Neels +3 more
openaire +4 more sources
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer [PDF]
International Journal of Molecular Sciences, 2021 Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutamide on PSMA expression.
Magdalena Staniszewska +11 more
openaire +5 more sources
Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2023 Objective(s): This study aimed to evaluate the therapeutic outcomes of 177Lutetium (177Lu)-PSMA-617 in metastatic castrate-resistant prostate cancer (mCRPC) patients, based on post-treatment imaging findings.
Seyed Ali Mirshahvalad +2 more
doaj +1 more source
MODERN OPPORTUNITIES OF PET/CT IN THE DIAGNOSIS OF PROSTATE CANCER
Сибирский онкологический журнал, 2021 The purpose is to present a modern data on the possibilities of positron emission computed tomography combined with computed tomography (PET/CT) in the diagnosis, staging and monitoring of prostate cancer (PC).Material and Methods.
V. V. Vyazmin +4 more
doaj +1 more source
Annals of Urologic Oncology, 2022 Background Prostate cancer (PCa) is the second most frequent malignancy (after lung cancer) in men worldwide .In prostate cancer, immunohistochemistry (IHC) has an important role in the diagnostic confirmation.
Amit V Varma +5 more
doaj +1 more source
Türk Biyokimya Dergisi, 2021 Sensitive and accurate techniques for early detection of prostate cancer, which has a good chance for successful treatment if detected early, are of utmost value. Our aim is to develop a sensitive chronoimpedimetric biosensor for detection of circulating
Uygun Zihni Onur, Girgin Sağin Ferhan
doaj +1 more source
Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA
He huaxue yu fangshe huaxue, 2023 A novel PSMA targeting molecule ［177Lu］Lu-DOTA-CPN-PSMA with high uptake and long retention in prostate cancer was developed, in which DOTA was used as the bifunctional chelator, glutamic acid-urea-lysine(Glu-Urea-Lys) was used as the targeting group ...
LUO Tian-wei +7 more
doaj +1 more source
Pharmaceuticals, 2020 The role of nuclear medicine in the management of oncological patients has expanded during last two decades. The number of radiopharmaceuticals contributing to the realization of theranostics/radiotheranostics in the context of personalized medicine is ...
Irina Velikyan
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2022 Objective To evaluate the diagnostic value of 18F-labeled PSMA PET/CT for regional lymph node metastasis in prostate cancer. Methods We searched PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP and Wanfang database from January 1, 2000 to May ...
ZENG Chunyuan, CHENG Yong, XU Hao
doaj +1 more source